The Development Pathway for Biosimilar Biotherapeutics.
作者信息
Zarbin Marco
机构信息
Institute of Ophthalmology and Visual Science, New Jersey Medical School, Rutgers University, Newark, USA.
出版信息
J Ophthalmic Vis Res. 2020 Aug 6;15(3):273-274. doi: 10.18502/jovr.v15i3.7444. eCollection 2020 Jul-Sep.
Abstract
摘要
相似文献
1
The Development Pathway for Biosimilar Biotherapeutics.生物类似药生物治疗剂的开发途径。
J Ophthalmic Vis Res. 2020 Aug 6;15(3):273-274. doi: 10.18502/jovr.v15i3.7444. eCollection 2020 Jul-Sep.
2
Glycosimilarity assessment of biotherapeutics 1: Quantitative comparison of the N-glycosylation of the innovator and a biosimilar version of etanercept.生物类似药的糖基相似性评估 1：依那西普创新药与生物类似药版本 N-糖基化的定量比较。
J Pharm Biomed Anal. 2018 May 10;153:182-185. doi: 10.1016/j.jpba.2018.02.021. Epub 2018 Feb 15.
3
[Experiences with biosimilar drugs in therapy].[生物类似药在治疗中的应用经验]
Vnitr Lek. 2015 Mar;61(3):207-8.
4
Biosimilar monoclonal antibodies: a science-based regulatory challenge.生物类似药单克隆抗体：基于科学的监管挑战。
Expert Opin Biol Ther. 2013 Feb;13(2):153-6. doi: 10.1517/14712598.2012.758710. Epub 2013 Jan 4.
5
Alkylsaccharides: circumventing oxidative damage to biotherapeutics caused by polyoxyethylene-based surfactants.烷基糖：规避聚氧乙烯基表面活性剂对生物治疗药物造成的氧化损伤。
Ther Deliv. 2013 May;4(5):567-72. doi: 10.4155/tde.13.19.
6
An Update on the Registration of Biosimilars in Malaysia.马来西亚生物类似药注册情况更新
Ther Innov Regul Sci. 2017 Jan;51(1):55-59. doi: 10.1177/2168479016664774. Epub 2016 Sep 27.
7
Monoclonal antibody: the corner stone of modern biotherapeutics.单克隆抗体：现代生物治疗的基石。
Yao Xue Xue Bao. 2012 Oct;47(10):1275-80.
8
Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.在类风湿关节炎和银屑病试验中，原研 TNF 抑制剂和生物类似药的疗效和安全性结局：系统文献回顾。
BioDrugs. 2018 Jun;32(3):193-199. doi: 10.1007/s40259-018-0283-4.
9
Recent advancements, challenges, and practical considerations in the mass spectrometry-based analytics of protein biotherapeutics: A viewpoint from the biosimilar industry.基于质谱的蛋白质生物治疗药物分析的最新进展、挑战和实际考虑因素：来自生物类似药行业的观点。
J Pharm Biomed Anal. 2018 Nov 30;161:214-238. doi: 10.1016/j.jpba.2018.08.024. Epub 2018 Aug 11.
10
On the glycosylation aspects of biosimilarity.关于生物类似药的糖基化方面。
Drug Discov Today. 2018 Mar;23(3):616-625. doi: 10.1016/j.drudis.2018.01.009. Epub 2018 Jan 11.
引用本文的文献
1
Expected Impact of Biosimilars on the Pharmaceutical Companies.生物类似药对制药公司的预期影响。
Iran J Med Sci. 2021 Sep;46(5):399-401. doi: 10.30476/IJMS.2021.92314.2356.
2
Intraocular Injection of StivantⓇ (A Biosimilar to Bevacizumab): A Case Series.玻璃体内注射StivantⓇ（贝伐单抗生物类似药）：病例系列
J Ophthalmic Vis Res. 2021 Jan 20;16(1):28-33. doi: 10.18502/jovr.v16i1.8248. eCollection 2021 Jan-Mar.
本文引用的文献
1
Safety of Intravitreal Injection of Stivant, a Biosimilar to Bevacizumab, in Rabbit Eyes.玻璃体内注射与贝伐单抗生物类似药Stivant在兔眼中的安全性。
J Ophthalmic Vis Res. 2020 Aug 6;15(3):341-350. doi: 10.18502/jovr.v15i3.7453. eCollection 2020 Jul-Sep.
2
Ophthalmic biosimilars: Lessons from India.眼科生物类似药：来自印度的经验教训。
Indian J Ophthalmol. 2019 Aug;67(8):1384-1385. doi: 10.4103/ijo.IJO_430_19.
3
Biotherapeutics and immunogenicity: ophthalmic perspective.生物疗法与免疫原性：眼科视角
Eye (Lond). 2019 Sep;33(9):1359-1361. doi: 10.1038/s41433-019-0434-y. Epub 2019 Apr 9.
4
Strengths, weaknesses and future challenges of biosimilars' development. An opinion on how to improve the knowledge and use of biosimilars in clinical practice.生物类似药研发的优势、劣势与未来挑战。改善生物类似药在临床实践中的认知和使用的意见。
Pharmacol Res. 2017 Dec;126:138-142. doi: 10.1016/j.phrs.2017.11.002. Epub 2017 Nov 4.
5
Science of Biosimilars.《生物类似药科学》。
J Oncol Pract. 2017 Sep;13(9_suppl):17s-23s. doi: 10.1200/JOP.2017.026062.
6
Regulatory considerations in oncologic biosimilar drug development.肿瘤生物类似药研发中的监管考量
MAbs. 2015;7(4):653-61. doi: 10.1080/19420862.2015.1040973.
7
Biosimilars advancements: Moving on to the future.生物类似药的进展：迈向未来。
Biotechnol Prog. 2015 Sep-Oct;31(5):1139-49. doi: 10.1002/btpr.2066. Epub 2015 Mar 16.
Zotero 插件